Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Esther Oomen–de Hoop"'
Autor:
Marjolijn M. Ladan, Titia G. Meijer, Nicole S. Verkaik, Cecile de Monye, Linetta B. Koppert, Esther Oomen-de Hoop, Carolien H. M. van Deurzen, Roland Kanaar, Julie Nonnekens, Dik C. van Gent, Agnes Jager
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract We developed a functional ex vivo anthracycline-based sensitivity test. Surgical resection material of primary breast cancer (BC) was used to determine criteria for the ex vivo sensitivity assay based on morphology, proliferation and apoptos
Externí odkaz:
https://doaj.org/article/131ad1d936bc40268bf604058db3be8d
Autor:
Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja deWeerd, Esther Oomen‐de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald deWit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job vanRiet, John W. M. Martens
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1898-1907 (2023)
Multiple prognostic biomarkers, including circulating tumour cell (CTC) counts, exist in metastatic castration‐resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy
Externí odkaz:
https://doaj.org/article/5586ded94d52426a8e1b34ae1e5d9078
Autor:
Sanne M. Buijs, C. Louwrens Braal, Stefan A. J. Buck, Noud F. van Maanen, Lonneke M. van der Meijden-Erkelens, Heleen A. Kuijper-Tissot van Patot, Esther Oomen-de Hoop, Lotte Saes, Sophia J. van den Boogerd, Liesbeth E. M. Struik, Quirine C. van Rossum-Schornagel, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Tamoxifen may lead to bothersome side effects contributing to non-compliance and decreased quality of life. Patients searching for relief are increasingly turning to cannabinoids such as CBD-oil. However, CBD-oil might affect tamoxifen pharm
Externí odkaz:
https://doaj.org/article/270e89bb85c04654be454a2dba613f34
Autor:
Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105074- (2024)
Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, so
Externí odkaz:
https://doaj.org/article/a26effef666d4b159c43d8ae59e8c674
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101955- (2023)
Summary: Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimert
Externí odkaz:
https://doaj.org/article/3a9954ccf1454c0c889fa14273839a4e
Autor:
Daan C. H. van Dorst, Sumeyye Kabadayi, Esther Oomen‐de Hoop, A.H. Jan Danser, Ron H. J. Mathijssen, Jorie Versmissen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 1 (2023)
Background Anti‐cancer vascular endothelial growth factor inhibitors (VEGFI) frequently induce a rise in blood pressure (BP). The most effective treatment of this BP rise is currently unknown, and risk factors and its association with survival rema
Externí odkaz:
https://doaj.org/article/59d3fa5ccc3d4b688b07134a4440606a
Autor:
Pauline A. J. Mendelaar, Jaco Kraan, Mai Van, Leonie L. Zeune, Leon W. M. M. Terstappen, Esther Oomen‐de Hoop, John W. M. Martens, Stefan Sleijfer
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 116-125 (2021)
Circulating tumor cells (CTCs) in the blood of cancer patients are of high clinical relevance. Since detection and isolation of CTCs often rely on cell dimensions, knowledge of their size is key. We analyzed the median CTC size in a large cohort of b
Externí odkaz:
https://doaj.org/article/abd8020dbc4e441798b1b1166cf05e04
Autor:
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: In breast cancer patients treated with the anti-estrogen tamoxifen, low concentrations of the active metabolite endoxifen are associated with more disease recurrence. We hypothesized that we could increase endoxifen concentrations by in
Externí odkaz:
https://doaj.org/article/258552e485654475a839962a4fd6a115
Autor:
Ruben A. G. van Eerden, Leni van Doorn, Femke M. de Man, Niels Heersche, Michail Doukas, Thierry P. P. van den Bosch, Esther Oomen-de Hoop, Peter de Bruijn, Sander Bins, Eman Ibrahim, Suzan Nikkessen, Lena E. Friberg, Stijn L. W. Koolen, Manon C. W. Spaander, Ron H. J. Mathijssen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Data from previous work suggests that there is no correlation between systemic (plasma) paclitaxel exposure and efficacy in patients treated for esophageal cancer. In this trial, we investigated ATP-binding cassette efflux transporter exp
Externí odkaz:
https://doaj.org/article/2da8bb17075a4bb7a21f579be94bb87f
Autor:
Liza G. G. van Lent, Nicole K. Stoel, Julia C. M. van Weert, Jelle van Gurp, Maja J. A. de Jonge, Martijn P. Lolkema, Eelke H. Gort, Saskia M. Pulleman, Esther Oomen-de Hoop, Jeroen Hasselaar, Carin C. D. van der Rijt
Publikováno v:
BMC Palliative Care, Vol 18, Iss 1, Pp 1-10 (2019)
Abstract Background Patients with advanced cancer for whom standard systemic treatment is no longer available may be offered participation in early phase clinical trials. In the decision making process, both medical-technical information and patient
Externí odkaz:
https://doaj.org/article/5147c75b4ff6452697ab6a687669a1e3